Search
Fuhong Hanlin: Initiation of Phase III Trial for Anti-HER2 Monoclonal Antibody Combination Therapy in the United States
1 day ago /
Read about 0 minute
Author：小编
HLX22, an innovative HER2-targeted monoclonal antibody developed by Fuhong Hanlin, exhibits a unique synergy with trastuzumab. This combination enhances the efficacy of HER2 receptor endocytosis by a substantial 40%-80%, thereby amplifying the blocking effect. Preclinical studies and Phase II trials have convincingly demonstrated the remarkable efficacy of HLX22 in conjunction with trastuzumab and chemotherapy for the treatment of HER2-positive gastric cancer. Currently, the Phase III clinical trial of HLX22 is underway, marking a significant milestone as no similar dual-targeted therapy has yet been approved globally for this indication.
-
C114 Communication Network -
Communication Home
7 X 24 Track global technological trends
